GKWIM
VRTX icon

Gerber Kawasaki Wealth & Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-335
Closed -$60K – 1093
2021
Q3 		$60K Buy
+335
New +$65.4K 0.01% 297

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's VRTX Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2021, closing a stake of 335 shares — an estimated $60K sold.

Gerber Kawasaki Wealth & Investment Management first reported a position in VRTX in Q3 2021 and held it in 1 quarter. The position peaked at $60K in Q3 2021. 1,034 funds tracked by Wall St. Rank hold VRTX as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Vertex Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 335 Vertex Pharmaceuticals shares in Q4 2021, an estimated $60K.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Vertex Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Vertex Pharmaceuticals position peaked at $60K in Q3 2021.
  • 1,034 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.